BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced today it has reached a remarkable milestone by winning five categories at the 2024 Pharmaceutical Technology Excellence Awards. The company was honored in Business Expansion, Research and Development (R&D), Innovation, Product Launches and Marketing, marking a significant achievement in its ongoing mission to advance cancer care through transformative technologies.
The Pharmaceutical Technology Excellence Awards, powered by GlobalData’s business intelligence, celebrate the pharmaceutical industry’s most impactful achievements.
“BostonGene’s accomplishments reflect the power of AI in revolutionizing cancer care and patient outcomes,” said Tina Ross, Global Awards Manager at GlobalData. “These awards highlight BostonGene’s pivotal role in reshaping cancer diagnostics and treatment, demonstrating how cutting-edge technology can accelerate and enhance patient-centric solutions in the pharmaceutical landscape.”
“This recognition by GlobalData highlights the impact of our work to transform cancer care through advanced, AI-driven solutions,” said Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene. “Winning across multiple categories showcases the breadth of our contributions, from R&D and diagnostics to clinical applications and patient care, inspiring us to keep advancing innovation in precision medicine.”
Leading in Business Expansion: Global Reach Through AI-Powered Multiomics
BostonGene’s accolade in Business Expansion highlights its AI-powered multiomics platform, which optimizes drug development and clinical trials on a global scale. By facilitating the precise matching of patients with optimal therapies, BostonGene’s platform has accelerated R&D, expanding its footprint across the United States, Europe and Japan. This expansion brings personalized cancer care to more patients worldwide, underscoring BostonGene’s global impact.
As a designated laboratory for the ComboMATCH and other prospective clinical trials, BostonGene is pioneering new techniques to optimize treatment strategies in multiple cancers. BostonGene’s collaboration with LigoChem Biosciences, where it serves as the study’s central laboratory on the TROP2-directed antibody-drug conjugate clinical trial, further solidifies its role as a pivotal clinical trial support partner, maximizing treatment outcomes through advanced multiomic profiling.
Innovative R&D: Pioneering Tumor Microenvironment Typing
Recognized for its pioneering work in R&D, BostonGene’s Tumor Microenvironment (TME) Typing represents a breakthrough in oncology. This biomarker utilizes comprehensive RNA sequencing data to classify the underlying biology of tumors, enabling the prediction of patient prognosis and immunotherapy response, leading to optimized therapy selection.
In partnership with Exigent Research on the ongoing BEGIN Study, BostonGene is advancing TME typing, aiming to validate its predictive capabilities and refine patient selection. This collaboration highlights the platform’s role in enhancing the success of cancer treatments through precision profiling.
A New Frontier in Oncology with Immune System Profiling
BostonGene’s innovation award reflects its development of a novel immune system profiling platform, which analyzes blood samples to predict immunotherapy responses. This non-invasive platform provides a more efficient alternative to traditional biomarkers, aiding in patient selection as well as response and toxicity monitoring in clinical trials.
BostonGene’s collaboration with the Parker Institute for Cancer Immunotherapy leverages this technology to explore the molecular underpinnings of immuno-oncology treatment and side effects. The platform’s success across various cancer types demonstrates its potential to reshape personalized cancer care and improve patient outcomes.
Transforming Product Launches with AI-Based Digital Pathology
BostonGene’s AI-powered digital pathology platform, which secured the Product Launches award, can streamline cancer diagnostics. By automating tissue analysis, the platform reduces human error and variability, offering more reliable results in biomarker identification.
This technology provides capabilities in immunohistochemistry (IHC), hematoxylin and eosin (H&E) staining and multiplex immunofluorescence testing, enabling the accurate detection of complex biomarkers. The platform’s comprehensive biomarker detection facilitates personalized treatment plans, reshaping how cancer patients are managed.
Excellence in Marketing through Digital Innovation
BostonGene’s digital marketing strategy earned the company the Marketing award, highlighting its success in promoting biopharma innovations. By utilizing a robust online presence and active engagement across social media, BostonGene has bolstered its brand visibility and solidified its position as a thought leader in precision medicine.
Through regular updates and research findings shared across platforms, BostonGene fosters meaningful discussions around the future of personalized medicine, keeping patients, healthcare providers, and the biopharma community well-informed about the latest advancements.
About BostonGene Corporation
BostonGene is a biotechnology company specializing in advanced computational biology and precision medicine. Founded in 2015, BostonGene has consistently pushed the boundaries of innovation to improve patient care and accelerate drug development. Our AI-powered multiomics platform decodes cancer patients’ molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets and recommend the most effective treatments. With advanced bioanalytics, an indication-specific cancer library and a next-generation CLIA-certified, CAP-accredited high-complexity laboratory, we deliver precise, clinically validated insights that drive precision medicine and advance oncology research. For more information, visit www.BostonGene.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241112225256/en/